ArticleJournal of stem cells & regenerative medicine2026
Article in Journal of stem cells & regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liver diseases remain a major global health burden, with limited treatment options for advanced hepatic dysfunction. Current treatment options are limited and mainly supportive, with liver transplantation being the only definitive therapy in advanced cases. Stem cell-based therapies have emerged as a promising alternative due to their regenerative and immunomodulatory properties. Stem cells can differentiate and produce identical daughter cells. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) hold promise for liver regeneration but show limited hepatic differentiation efficiency. Preconditioning with FGF and IGF may enhance their differentiation, survival, and functional potential. This study aims to investigate the effect of FGF and IGF pre-treatment on the differentiation capacity of UC-MSCs and their potential application in regenerative therapy for liver fibrosis or cirrhosis. Methods: Cell viability was evaluated through MTT, crystal violet, and trypan blue assays. For the assessment of differentiation potential, ELISA and Immunocytochemistry of HNF4α and ASGPR1 were performed, for angiogenesis and apoptosis, ELISA of VEGF and p53 were performed. Furthermore, antioxidant enzyme activity was also assessed. Results: UC-MSCs preconditioned with FGF and IGF exhibited significantly enhanced viability and reduced cell death, as confirmed by MTT, crystal violet, trypan blue assays, and ELISA of VEGF and P53. ELISA and immunocytochemistry of HNF4α and ASGPR1 demonstrated marked upregulation of these hepatic markers in the preconditioned groups. The gene expression analysis confirmed superior regenerative potential in the FGF+IGF-treated group. Antioxidative analysis further validated a higher level of antioxidative potential in preconditioned cells. Conclusion: Preconditioned UC-MSCs offer a promising cellbased alternative to liver transplantation by enhancing regeneration, reducing apoptosis, promoting angiogenesis and increasing antioxidant defense in damaged liver tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.